At the news
? BEARISHIMPACT 6/10 EFFECT filed Jul 20, 2026 at 00:15 ET
Indaptus Therapeutics' S-3 registration statement (File No. 333-297088) became effective on July 17, 2026, enabling selling stockholders Ting Yang, Lina Deng, and David Lazar to resell up to 18,864,000 shares (~14.2% of outstanding). The company receives no proceeds and has discontinued all clinical development, with its auditor expressing substantial doubt about going concern. This effectiveness removes the final procedural barrier to insider selling, adding immediate overhang to a stock already under severe fundamental distress.
- S-3 shelf became effective on 2026-07-17, allowing resale of up to 18,864,000 shares by selling stockholders.
- Company discontinued all clinical development of lead candidate Decoy20 and has no active programs.
- Auditor has expressed substantial doubt about Indaptus' ability to continue as a going concern.
- Indaptus will not receive any proceeds from the resale of shares under this shelf.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access